



---

## **Early P2Y<sub>12</sub> Inhibitor Single Antiplatelet Therapy for High-Bleeding Risk Patients After Stenting — PENDULUM Mono 24-Month Analysis —**

---

Yoshihisa Nakagawa, MD, PhD; Kazushige Kadota, MD, PhD; Koichi Nakao, MD, PhD;  
Junya Shite, MD, PhD; Hiroyoshi Yokoi, MD, PhD; Ken Kozuma, MD, PhD;  
Kengo Tanabe, MD, PhD; Takashi Akasaka, MD, PhD; Toshiro Shinke, MD, PhD;  
Takafumi Ueno, MD, PhD; Atsushi Hirayama, MD, PhD; Shiro Uemura, MD, PhD;  
Raisuke Iijima, MD, PhD; Atsushi Harada; Takeshi Kuroda, PhD; Atsushi Takita;  
Yoshitaka Murakami, PhD; Shigeru Saito, MD, PhD; Masato Nakamura, MD, PhD

## Supplementary Materials

### Supplementary Text. Inclusion and exclusion criteria for patients in PENDULUM mono

The inclusion criteria were as follows:

1. Patients aged  $\geq 20$  years at the time of informed consent
2. Patients indicated for percutaneous coronary intervention (PCI)
3. Patients for whom a prasugrel treatment period of  $\geq 12$  months after PCI was planned
4. Patients who met at least one of the following criteria and were not considered appropriate candidates for long-term combination treatment with aspirin:

[1] Peptic ulcer

[2] Bleeding history (e.g., intracranial hemorrhage, lung bleeding, gastrointestinal bleeding, and fundus bleeding, among others)

[3] Bleeding tendency (e.g., hemoglobin  $< 11$  g/dL before PCI)

[4] Renal function impairment of (e.g., renal failure, renal dialysis, estimated glomerular filtration rate  $< 60$  before PCI)

[5] Needing continuous non-steroidal anti-inflammatory drugs (other than aspirin) after PCI

[6] Needing continuous oral anticoagulants after PCI

[7] Aged  $\geq 75$  years at the time of informed consent

[8] Body weight  $\leq 50$  kg

[9] Having other bleeding risks according to the attending physician's judgement


The exclusion criteria were as follows:

1. Needing  $\geq 6$  months of dual antiplatelet therapy due to their thrombotic risk
2. Patients with a bleeding event (e.g., hemophilia, intracranial bleeding, gastrointestinal bleeding, urinary bleeding, hemoptysis, vitreous hemorrhage)
3. PCI lesion at the graft site
4. Patients participating or planning to participate in other clinical studies before the completion of the follow-up period of this study
5. Participating in the PENDULUM registry


**Supplementary Figure.** Proportion of patients receiving DAPT and SAPT over time up to 24 months after PCI in the de-escalation strategy group and conventional strategy group

DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy.

### De-escalation strategy group



### Conventional strategy group



■ DAPT      ■ SAPT  
■ DAPT (Prasugrel + aspirin)      ■ SAPT (Prasugrel)